Astrid Zimmermann

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Circulating Tumor

Top Venues

Molecular cancer therapeutics

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Ukhyun Jo, Yashuhiro Arakawa, Astrid Zimmermann, Daiki Taniyama, Makito Mizunuma, Lisa M Miller Jenkins, Tapan Maity, Suresh Kumar, Frank T Zenke, Naoko Takebe, Yves Pommier
The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs. Molecular cancer therapeutics (2024)
Ukhyun Jo, Yashuhiro Arakawa, Astrid Zimmermann, Daiki Taniyama, Makito Mizunuma, Lisa M Miller Jenkins, Tapan Maity, Suresh Kumar, Frank T Zenke, Naoko Takebe, Yves Pommier
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs. Molecular cancer therapeutics 23 (7) (2024)
Audrey Turchick, Astrid Zimmermann, Li-Ya Chiu, Heike Dahmen, Brian Elenbaas, Frank T Zenke, Andree Blaukat, Lyubomir T Vassilev
Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors. Molecular cancer therapeutics (2023)
Marta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, Jadwiga Nieminuszczy, John Alexander, Feifei Song, Malgorzata Dylewska, Ronan Broderick, Rachel Brough, Astrid Zimmermann, Frank T Zenke, Bora Gurel, Ruth Riisnaes, Ana Ferreira, Theodoros I Roumeliotis, Jyoti Sharma Choudhary, Stephen J Pettitt, Johann S de Bono, Andres Cervantes, Syed Haider, Wojciech Niedzwiedz, Christopher J Lord, Irene Y Chong
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance. Cancer research 82 (21) (2022)
Astrid Zimmermann, Frank T Zenke, Li-Ya Chiu, Heike Dahmen, Ulrich Pehl, Thomas Fuchss, Thomas Grombacher, Beatrix Blume, Lyubomir T Vassilev, Andree Blaukat
A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies. Molecular cancer therapeutics 21 (6) (2022)